Mymetics Corporation (MYMX)

Overview

Mymetics Corporation, originally known as ICHOR Corporation before its renaming in July 2001, stands out as a pioneering entity focused on the research and development of innovative vaccines targeting infectious and life-disabling diseases. With its foundation laid in 1990, the company has solidified its presence in Epalinges, Switzerland, dedicating its efforts towards addressing some of the most pressing health challenges. Leveraging a strategic blend of collaborations with esteemed institutions such as the Texas Biomedical Research Institute, PATH Malaria Vaccine Initiative, the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, and Sanofi Pasteur Biologics, LLC, Mymetics Corporation drives forward its mission. These partnerships are centered on the development and production of virosome-based vaccine formulations, notably for a malaria transmission-blocking vaccine candidate, highlighting the company’s innovative approach in the vaccine research domain.

Products and Services

• HIV-1/AIDS Vaccine Candidate

  At the forefront of its innovative pipeline, Mymetics Corporation is developing a promising vaccine candidate aimed at combating HIV-1/AIDS, a critical global health issue. This initiative represents a significant stride towards addressing the challenges posed by HIV-1.

• Covid-19 Vaccine Candidate

  In response to the global pandemic, Mymetics has pivoted resources towards the development of a Covid-19 vaccine candidate. This effort showcases the company’s agility and commitment to contributing to global health emergencies.

• Intra Nasal Influenza Vaccine Candidate

  Pioneering a novel approach to influenza vaccination, Mymetics is working on an intra-nasal vaccine candidate. This innovative strategy aims to enhance user convenience and improve vaccine uptake rates.

• Respiratory Syncytial Virus (RSV) Vaccine Candidate

  Addressing another critical area of respiratory health, Mymetics’ RSV vaccine candidate targets the Respiratory Syncytial Virus, aiming to protect vulnerable populations from this prevalent infections.

• Malaria Vaccine Candidate

  Through collaboration with key global health entities, Mymetics is advancing a vaccine candidate against malaria. This effort is part of the broader initiative to block malaria transmission, promising a transformative impact on malaria control and eradication efforts.

• Chikungunya Vaccine Candidate

  Expanding its infectious disease portfolio, Mymetics is also developing a vaccine candidate for Chikungunya, a virus that has seen sporadic outbreaks in various parts of the world, underlining the company’s commitment to addressing emerging health threats.